Meldola

• The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR-042) Study Ended recruitment
  2024-510605-28-00 5 2018-11-27 Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
• Study to determine safety, efficacy and tolerability of Venetoclax in combination with Fludarabine, Citarabine and Idarubicin to achieve "th … Ended recruitment
  2023-510517-26-00 9 2018-10-26 Acute Myeloid Leukemia
• Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma Ended recruitment
  2022-501966-23-00 5 2018-09-11 Resected High-Risk Stage II Melanoma
• STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA (Dara-VM … Ended recruitment
  2024-512049-17-00 6 2018-09-05 Newly diagnosed MM patients >= 65 years old or ineligible for autologo
• A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma Ended recruitment
  2023-504802-12-00 7 2018-05-16 Lymphoma of B-cell origin
• Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Stage II, IIIA-Resectable IIIB (N2) NSCLC Ended recruitment
  2023-504820-24-00 5 2018-03-21 Neoadjuvant/Adjuvant treatment for participants with Resectable Stage
• Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE) Ended recruitment
  2023-510444-21-00 5 2017-11-24 Neuroendocrine tumours of gastroenteric or pancreatic origin
• A Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small C … Ended recruitment
  2023-507500-31-00 10 2017-08-22 Advanced or metastatic Non-small cell lung cancer (NSCLC)
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended recruitment
  2023-509671-17-00 5 2017-07-12 Breast Cancer
• A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Ended recruitment
  2023-510298-33-00 4 2016-11-29 Prostate Cancer
• Sustained treatment-free period in the course of a disease when symptoms become less severe in BCR-ABL+ chronic myeloid leukemia: a prospect … Ended recruitment
  2023-510434-83-00 6 2016-10-17 Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)
• A study to decide what is the highest dose of CC-220 to take alone and with other standard of care treatments to assess the side effects, ef … Ended recruitment
  2024-510799-19-00 9 2016-08-09 Multiple Myeloma
• PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers … Ended recruitment
  2024-514841-12-00 5 2015-10-27 To determine whether the addition of palbociclib to adjuvant endocrine
• A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly sympto … Ended recruitment
  2023-510453-41-00 5 2015-10-26 Castration resistant prostate cancer patients metastatic to bone.
• A trial to learn how well osimertinib (AZD9291) works to prevent cancer from coming back after surgery and how safe it is compared to the pl … Ended recruitment
  2023-506524-82-00 5 2015-10-21 Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirme
• An international study to evaluate the safety and effectiveness of enzalutamide plus leuprolide, enzalutamide alone, and leuprolide alone in … Ended recruitment
  2024-513521-23-00 5 2015-08-19 Prostate Cancer
• A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obi … Ended recruitment
  2023-509348-84-00 5 2015-04-27 Chronic Lymphocytic Leukemia
• An open-label extension study of pertuzumab administered on its own or in combination with other anti-cancer therapies in patients previousl … Ended recruitment
  2023-505102-42-00 5 2014-12-18 Solid Malignant Tumors
• A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab al … Ended recruitment
  2024-511640-11-00 5 2014-05-15 Follicular lymphoma
• Phase 1b Study of Tarlatamab in Combination with YL201 with or without Anti-PD-L1 in Subjects with Extensive Stage Small Cell Lung Cancer (D … Halted
  2024-515903-21-00 3 2025-10-31 Extensive Stage Small Cell Lung Cancer (ES-SCLC)
• A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors Halted
  2024-516916-93-00 3 2025-09-08 This study will be a Phase 1b, global, multicenter, open-label, 2-part
• A trial to understand if AZD0486 is safe and helps in people with Relapsed or Refractory B-cell acute lymphoblastic leukemia (B-ALL) Halted
  2023-505840-20-00 9 2024-08-16 B-Cell Acute Lymphoblastic Leukaemia
• A study to evaluate novel immunotherapy combinations in participants with advanced non-small cell lung cancer (NSCLC) Halted
  2023-508730-34-00 9 2024-07-10 Non-small cell lung cancer (NSCLC): - Locally advanced NSCLC where par
• Use of circulating tumor dna test to intensify post-operative treatment of patients with resected colon cancer. Halted
  2024-515152-20-00 4 2023-03-02 Stage III and high-risk stage II resected colon cancer patients.

Showing 361–384 of 447 trials